At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 161 enrolled
Drug / intervention
SPARC0913drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating SPARC0913 for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 161 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the long-term safety of SPARC0913. A multicenter, open label, non-randomized, uncontrolled, single group assignment, safety study of subjects with primary open angle glaucoma or ocular hypertension is planned. Subjects will receive study medication for a period of 24-weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartNov 2010
Primary CompletionJun 2012
TodayJul 2026
First PostedJul 24, 2009
Enrollment StartNov 1, 2010
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 16.9 years ago
Interventions
SPARC0913drug
One drop of SPARC0913 in affected eye once daily for 24 weeks